Buzz Stocks: Tesla Motors Inc, Endologix, Inc., and Seattle Genetics, Inc.

Today's stocks to watch in the news include Tesla Motors Inc (NASDAQ:TSLA), Endologix, Inc. (NASDAQ:ELGX), and Seattle Genetics, Inc. (NASDAQ:SGEN)

Dec 27, 2016 at 9:19 AM
facebook twitter linkedin

U.S. stock futures are pointing to a mixed open, as traders return from the long holiday weekend. Among specific equities in the spotlight today are electric car maker Tesla Motors Inc (NASDAQ:TSLA), medical device stock Endologix, Inc. (NASDAQ:ELGX), and biotech Seattle Genetics, Inc. (NASDAQ:SGEN). Here's a quick look at what's driving TSLA, ELGX, and SGEN.

  • TSLA could get a boost today, thanks to news Panasonic will invest roughly $256 million in a New York factory that will begin producing photovoltaic cells and modules next summer. Tesla Motors Inc stock has mostly been moving lower since peaking at $269.34 back in April, though the shares have found support near $180 in recent weeks, and managed a close at $213.34 on Friday -- putting them just below their 200-day moving average. Still, analysts have sided with short sellers and options traders, taking a bearish stance on TSLA. Seventeen brokerage firms track the stock, but just three recommend buying it. 

  • ELGX is selling off in electronic trading, down 14.6%, after the company announced it has put a temporary hold on its AFX system due to what's being called a manufacturing issue. The stock is no stranger to huge losses, as it has lost more than half its value since its July high of $14.50, last seen at $7.19. Understandably, short sellers continue to target Endologix, Inc., with short interest now sitting at its highest point in at least 14 years. In fact, more than one-fifth of the stock's float is controlled by these bears. 

  • SGEN is also getting crushed ahead of the open, dropping 16% so far, on news the Food and Drug Administration (FDA) has placed a hold on a number of clinical trials for the company's leukemia treatment, vadastuximab talirine. While the shares have edged lower in recent weeks, they've still enjoyed a solid 2016, adding 37.8% to trade at $61.86, while touching an all-time high of $75.36 just last month. Short-term options traders may be well-positioned for today's potential pullback, though. Seattle Genetics, Inc. has a Schaeffer's put/call open interest ratio (SOIR) of 1.35, which ranks in the 99th annual percentile. Said simply, options traders targeting contracts that expire in the next three months are overwhelmingly put-skewed. 

Stay on top of overnight news & big morning movers. Sign up now for Schaeffer's Opening View.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!



Special Offers from Schaeffer's Trading Partners